4 Results for "

TTP 488

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "TTP 488" in MCE Product Catalog:

17
17 Cited Publications
Referencia número: HY-50682
No. CAS: 603148-36-3
Synonyms: TTP488; PF-04494700
Target:  

Amyloid-β

Áreas de investigación:  

Neurological Disease Cancer

Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .
loading...
    loading...
Referencia número: HY-50682S
Synonyms: TTP488-d9; PF-04494700-d9
Azeliragon-d9 (TTP488-d9) is the deuterium labeled Azeliragon (HY-50682). Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .
loading...
    loading...
Referencia número: HY-50682A
No. CAS: 1284150-65-7
Synonyms: TTP488 dihydrochloride; PF-04494700 dihydrochloride
Target:  

Amyloid-β

Áreas de investigación:  

Neurological Disease Cancer

Azeliragon dihydrochloride (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon dihydrochloride also can cross the blood-brain barrier (BBB) .
loading...
    loading...
Referencia número: HY-50682R
No. CAS: 603148-36-3
Synonyms: TTP488 (Standard); PF-04494700 (Standard)
Áreas de investigación:  

Neurological Disease Cancer

Azeliragon (Standard) is the analytical standard of Azeliragon. This product is intended for research and analytical applications. Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .
loading...
    loading...